Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05483296
Other study ID # 2022-00432
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 22, 2022
Est. completion date June 20, 2023

Study information

Verified date December 2023
Source University Psychiatric Clinics Basel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many teenagers are familiar with this: on school days, they have to get up early; during the day, they hardly get any light exposure; in the evening, they go to bed late - and are then tired at school the next day! Around the world, teenagers are sleep deprived, with studies suggesting that almost half (~45%) suffer from inadequate sleep. Previous investigations have shown that people's sleep-wake rhythm is related to the light conditions that they are exposed to during the day and at night. However, little is known about how different light levels in the afternoon can modulate teenagers' sleep and their bodily responses to light in the late evening. Therefore, the investigators aim to study which lighting conditions have a favourable effect on these aspects and how the potentially harmful effects of light at night can be prevented.


Description:

Light exposure during adolescence seems to be the critical component of a vicious circle. Due to the maturation of sleep-wake regulatory systems in combination with progressively ill-timed exposure to light and early school start times, teenagers suffer from the accumulation of sleep depth during school days. Therefore, the proposed study investigates whether the physiological and alerting effects of late evening light exposure in adolescents depend on the intensity of light exposure in the preceding afternoon (primary endpoint: evening melatonin concentration). The investigators aim to describe dose-response relationships, where the "dose" is the preceding (real-world applicable) afternoon light intensity (< 10 lx, ~100 lx, or >1000 lx EDI, three-hour duration), and the "responses" are the adolescents' physiological and alerting responses to evening light exposure (~100 lx melanopic EDI, 4.5-hour duration). By this route, the researchers can explore whether increasing afternoon light exposure is a feasible target for ameliorating the detrimental effects of artificial light at night and promoting healthier sleep-wake regulation during adolescence.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date June 20, 2023
Est. primary completion date June 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 17 Years
Eligibility Inclusion Criteria: - Healthy - Capable of judgment - Normal BMI (Age-related Body-Mass-Index Percentile > P3 & < P97; approx. corresponding to 28.5 = BMI = 16) - Signed consent form of participants - Signed consent form of a legal representative Exclusion Criteria: - Pregnancy or breastfeeding (only female) - Current participation in other clinical trials - Extreme chronotype (Extreme early or late chronotype/mid sleep time: mid-sleep time < 1:00 / > 7:00) - Extremely short or long sleep durations during school- or work days (< 6 hours > 11 hours) - Sleep disorders - High myopia (< -6 diopters) - High hyperopia (> +6 diopters) - Non-normal best-corrected visual acuity (BCVA < 0.5 [20/40]) - General health concerns or disorders, including heart and cardiovascular, neurological, nephrological, endocrinological, and psychiatric conditions - Ophthalmological or optometric conditions - Medication impacting visual, neuroendocrine, sleep, and circadian physiology - Drug and alcohol use (urinary drug screening & breathalyzer test) - Non-compliance with sleep-wake times: >1 deviation from ±60 minute window sleep and wake-up time - Non-compliance with caffeine intake (> 1 times caffeine intake) - Transmeridian travel (>2 time zones) <1 month prior to the first session of the study - shift work <3 months prior to the beginning of the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Low light condition
During the "Dim" light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (<5 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level.
Moderate light condition
During the "Moderate" light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (~100 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level.
High light condition
During the "High" light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (>1000 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of ~100 lx melanopic EDI at the participants' eye level.

Locations

Country Name City State
Switzerland Psychiatric University Clinics (UPK), Centre for Chronobiology Basel Canton Of Basel City

Sponsors (1)

Lead Sponsor Collaborator
University Psychiatric Clinics Basel

Country where clinical trial is conducted

Switzerland, 

References & Publications (9)

Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990 May;52(1-2):29-37. doi: 10.3109/00207459008994241. — View Citation

Chellappa SL, Munch M, Blatter K, Knoblauch V, Cajochen C. Does the circadian modulation of dream recall modify with age? Sleep. 2009 Sep;32(9):1201-9. doi: 10.1093/sleep/32.9.1201. — View Citation

Gabel V, Kass M, Joyce DS, Spitschan M, Zeitzer JM. Auditory psychomotor vigilance testing in older and young adults: a revised threshold setting procedure. Sleep Breath. 2019 Sep;23(3):1021-1025. doi: 10.1007/s11325-019-01859-7. Epub 2019 May 8. — View Citation

Galland BC, Short MA, Terrill P, Rigney G, Haszard JJ, Coussens S, Foster-Owens M, Biggs SN. Establishing normal values for pediatric nighttime sleep measured by actigraphy: a systematic review and meta-analysis. Sleep. 2018 Apr 1;41(4). doi: 10.1093/sleep/zsy017. — View Citation

Hagenauer MH, Perryman JI, Lee TM, Carskadon MA. Adolescent changes in the homeostatic and circadian regulation of sleep. Dev Neurosci. 2009;31(4):276-84. doi: 10.1159/000216538. Epub 2009 Jun 17. — View Citation

Lo JC, Lee SM, Lee XK, Sasmita K, Chee NIYN, Tandi J, Cher WS, Gooley JJ, Chee MWL. Sustained benefits of delaying school start time on adolescent sleep and well-being. Sleep. 2018 Jun 1;41(6):zsy052. doi: 10.1093/sleep/zsy052. — View Citation

Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl). 1980;71(2):173-9. doi: 10.1007/BF00434408. — View Citation

Santhi N, Ball DM. Applications in sleep: How light affects sleep. Prog Brain Res. 2020;253:17-24. doi: 10.1016/bs.pbr.2020.05.029. Epub 2020 Jul 25. — View Citation

Spitschan M, Woelders T. The Method of Silent Substitution for Examining Melanopsin Contributions to Pupil Control. Front Neurol. 2018 Nov 27;9:941. doi: 10.3389/fneur.2018.00941. eCollection 2018. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Ambulant light history. To account for participants' light exposure before they arrive at the experimental site, ambulatory light exposure will be assessed throughout the three weeks of the experiment with actimetry devices (Condor ActTrust). Additionally, participants will be asked to estimate their duration of outdoor light exposure daily. During the experiment, participants will further be instructed to wear a lightweight light sensor. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Other Actigraphy Compliance to regular sleep-wake cycles over three weeks will be monitored with the actimetry device starting five days before the first experimental session (baseline + adaptation night) and ending with the final session. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Other Visual comfort & well-being An adapted German version of the first six items of the Visual Comfort Scale (VCS) will be used to assess the participant's visual comfort under the different lighting conditions. Additionally, participants will rate their momentary affect and well-being in relation to mood, hunger, relaxation, and motivation. Items are rated on a 7-point Likert-type scale (1-7) with higher values corresponding to a higher manifestation of the characteristic (for instance well-being, the brightness of the light etc.) Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Other Sleep diary Volunteers will report their sleep and wake episodes using a sleep-wake diary (like a questionnaire). Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Other Sleep quality In the mornings after the laboratory sleep, participants will additionally fill in a sleep quality questionnaire (Leeds Sleep Evaluation Questionnaire; LSEQ). The LSEQ is a 10-item, subjective, self-report measure that includes a visual analogue scale, where every item is scored from 0 to 10 where 10 corresponds to a higher manifestation of the characteristic (for instance tiredness). Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Other Dream recall In the mornings after the laboratory sleep, participants will additionally fill in a dream recall questionnaire (Sleep Mentation Questionnaire) which addresses numerous characteristics of dream recall, such as the number of dreams, emotionality, vividness, pleasantness, hostility, and colourfulness, on a Likert-point scale (1: greatly, 2: fairly, 3: little, and 4: not at all). Higher values on the scale correspond to a lower frequency of dreams. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Primary Salivary melatonin Salivary melatonin. Saliva samples (>1 mL) will be taken from the participants every 30 Minutes using Salivettes. The Salivettes will be centrifuged, the cotton part removed and immediately frozen at -20°C. At a later point, melatonin [in pg] will be determined in these samples by double-antibody radioimmunoassay (RIA). To quantify melatonin suppression, the analytic team will calculate the area under the curve (AUC) for each laboratory condition. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Sleep Onset Latency (PSG-derived) The investigators will operationalise Sleep Onset Latency according to the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events (time interval from lights out to the first PSG-derived sleep epoch in minutes). Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Slow wave activity (PSG-derived) The investigators will examine slow-wave activity (SWA; delta power density between 0.5 and 4.5 Hz) during the first sleep cycle. EEG slow-wave activity (SWA) (i.e., delta power density between 0.5 and 4.5 Hz) will be calculated as an indicator of sleep propensity across the night within each non-rapid eye movement NREM part of a sleep cycle. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Sleep stages (PSG-derived) The investigators will score the PSG-derived sleep stages and arousals according to the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Subjective sleepiness The investigators will assess subjective sleepiness using the single-item 9-point Karolinska Sleepiness Scale (KSS) - a well-validated, highly sensitive subjective Likert-type measurement scale for subjective sleepiness.
Scores range from 1 to 9 with higher values on the scale corresponding to higher sleepiness.
Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Vigilant attention Objective alertness will be measured using a modified auditory Psychomotor Vigilance Test (aPVT). After a response, the next tone will be played randomly after 2-10 s. The reaction time data will focus on mean 1/reaction time (mean 1/RT), the most sensitive measure for a slight deviation in sleep pressure. Mean 1/RT will be calculated after the removal of false starts and lapses. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Melanopsin sensitivity (pupillary light response) The investigators will measure changes in the pupil area using silent substitution pupillography and examine the differences between melanopsin response amplitude before the afternoon light condition (pre-light treatment) and the melanopsin response amplitude after the afternoon light condition (post-light treatment). Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Skin temperature Skin temperature will be continuously monitored with six surface temperature thermocouples placed on proximal and distal regions of the body surface. Skin temperatures (distal & proximal) and the distal-proximal skin temperature gradient (DPG) will be calculated. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Objective sleepiness 1 The volunteers will perform a Karolinska Drowsiness Test (KDT) three times during scheduled wakefulness. During the KDT, participants fixate on a point on the wall from a one-meter distance for five minutes (eyes open). These sessions will provide EEG data with relatively few artefacts. As the first indicator for objective sleepiness, EEG-derived alpha/theta ratio will be calculated. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
Secondary Objective sleepiness 2 The volunteers will perform a Karolinska Drowsiness Test (KDT) three times during scheduled wakefulness. During the KDT, participants fixate on a point on the wall from a one-meter distance for five minutes (eyes open). These sessions will provide EEG data with relatively few artefacts. As the second indicator for objective sleepiness, electro-oculogram-derived (EOG-derived) slow-eye movements will be calculated. Through study completion, estimated 1.5 years (within 3 weeks for each participant)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1